Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
Filed with ASX · · 9 pages · English
The Appendix 4C lodged earlier today reported in item 1.9 a “Net cash from / (used in) operating activities” result of 117,338 for the quarter and year to date. This number should read 17,338. This has now been corrected and reflected in the Appendix 4C attached. CLINUVEL PHARMACEUTICALS LTD released its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 July to 30 Septe
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- S&P DJI Announces September 2022 Quarterly Rebalance
- Appendix 4E and Annual Report 2022
- Positive Final Results in Stroke Study CUV801
- ACTH Manufacturing Update
- afamelanotide in Stroke (AIS) - Positive Preliminary Results
Later from Clinuvel Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4E and Annual Report to Shareholders 2023
- CUV Appendix 4D Half Year Report
- SCENESSE provides photoprotection in variegate porphyria
- New case of SCENESSE efficacy in vitiligo presented at AAD
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals